Companies / GILD vs MRNA
GILD vs MRNA: Gilead Sciences and Moderna
Gilead Sciences (GILD) reported $29.4B in revenue against a 28.9% net margin, while Moderna (MRNA) reported $1.9B at a -145.2% net margin, most recently.
| Metric | GILD | MRNA |
|---|---|---|
| Revenue | $29.4B | $1.9B |
| Net Income | $8.5B | $-2.8B |
| Gross Margin | 78.8% | 55.3% |
| Operating Margin | 34.0% | -158.1% |
| EPS (Diluted) | $6.78 | $-7.26 |
| Free Cash Flow | $9.5B | $-2.1B |
| Total Debt | $24.9B | $0.6B |
| P/E Ratio | 18.1× | n/m |
| P/B Ratio | 6.7× | 1.3× |
| Stock Price | $167.53 | $241.26 |
Free: last 5 years
| Fiscal year | FY2016 🔒 | FY2017 🔒 | FY2018 🔒 | FY2019 🔒 | FY2020 🔒 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| GILD Revenue | ••••• | ••••• | ••••• | ••••• | ••••• | $27.3B | $27.3B | $27.1B | $28.8B | $29.4B |
| MRNA Revenue | ••••• | ••••• | ••••• | ••••• | ••••• | $18.5B | $19.3B | $6.8B | $3.2B | $1.9B |